AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04805736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Standard of care breast conserving surgery or radical mastectmoy
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05554406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05092282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT-5
Description: Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06332534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets
Study NCT06232642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin, iron and B12 in Whey Protein
Description: Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
Study NCT06232642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin, Iron and B12 in Rice Protein
Description: Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
Study NCT06232642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin, Iron and B12 in Maltrodextrin
Description: Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
Study NCT06144619 — intervention group
Intervention type: GENETIC
Intervention: Genomic and Histological Evaluation
Description: Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
Study NCT06279949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider training
Description: Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
Study NCT06760637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: endocrine therapy
Study NCT06760637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abemaciclib
Description: CDK4/6 inhibitor
Study NCT06760637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palbociclib
Description: CDK4/6 inhibitor
Study NCT06760637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribociclib
Description: CDK4/6 inhibitor
Study NCT06775899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC-Based Ultrasound Training Tool
Description: An interactive, PowerPoint-based PC tool designed to simulate pathology recognition and ultrasound image optimization for medical students. It provides real ultrasound videos and images, allowing students to practice diagnostic interpretation and image acquisition in a structured training format.
Study NCT06775899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Ultrasound Simulator (VausSim)
Description: A medium-cost ultrasound simulator used for hands-on training in thoracic and abdominal ultrasound. It allows medical students to practice probe handling, image acquisition, and pathology recognition in a controlled simulation environment.
Study NCT06778850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDR-001
Description: Oral administration of small molecule MDR-001 tablets
Study NCT06778850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palcebo
Description: Administered orally placebo
Study NCT06778590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric technique in third molar germectomy
Description: Application of piezoelectric technique in third molar germectomy procedures
Study NCT06778590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique in third molar germectomy
Description: Application of traditional technique in third molar germectomy procedures
Study NCT06778603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a targeted probe B7H3-IRDye800CW
Description: B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
Study NCT06779643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Description: Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
Study NCT06779643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Brachial Plexus Block
Description: Patients were positioned supine with the head slightly turned to the contralateral side to expose the supraclavicular fossa. The injection site was prepared using standard aseptic techniques. Under ultrasound guidance, a needle was advanced to the vicinity of the brachial plexus. Aspiration was performed to confirm the absence of blood return before the slow, incremental injection of either liposomal bupivacaine \[adult dose: 133 mg (10 mL) to 266 mg (20 mL)\] or ropivacaine \[adult dose: 20 mL of 0.5% ropivacaine, administered via continuous infusion at a rate of 5-10 mL/h; pediatric dose: 0.1% ropivacaine at 0.1-0.2 mL/kg, administered via continuous infusion at 0.05-0.15 mL/kg/h\]. Patient responses were closely monitored throughout the procedure.
Study NCT06777680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)
Description: oral suspension, 10 ml twice a day (every 12 hours) for 7 days
Study NCT06777680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension,10 ml twice a day (every 12 hours) for 7 days
Study NCT06777680 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thrombectomy
Description: Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
Study NCT06279949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic protocols
Description: Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
Study NCT06777680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
Study NCT06778668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with bupivacaine only
Description: Patients undergoing laparoscopic cholecystectomy will receive TAP block with bupivacaine only after induction and before the surgical procedure begins.
Study NCT06778668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with bupivacaine and fentanyl
Description: Patients undergoing laparoscopic cholecystectomy will receive a TAP block with bupivacaine and fentanyl after induction and before the surgical procedure begins
Study NCT05126992 — intervention group
Intervention type: BIOLOGICAL
Intervention: AZD1222
Description: Covid-19 AstraZeneca Vaccine
Study NCT05214729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fast ultrafiltration challenge
Description: The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared.
Study NCT05214729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Slow ultrafiltration challenge
Description: The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared.
Study NCT06777992 — intervention group
Intervention type: OTHER
Intervention: Home topographic scans
Description: Patients randomized to the Intervention arm of the trial will additionally use Momentum SpineTM assessment from home at 2-month intervals. If a progression is detected using Momentum SpineTM the participant will be promptly invited to acquire a second set of scans for confirmation. In case of confirmation of the progression using the images from the repeated scans, the scan results will be sent to their local orthopedic surgeon.
Study NCT06777836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalised Discharge training
Description: Discharge education also contributes to the empowerment of diabetic surgery patients in diabetes management. During the training process, patients will be informed about blood glucose control, diet, exercise and medication management.
Study NCT06777732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan
Description: Potassium-competitive acid blocker
Study NCT06777732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keverprazan
Description: Potassium-competitive acid blocker
Study NCT06777732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT06777732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT06777732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication
Study NCT06777732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Gastric mucosal protectant
Study NCT06778733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphane citrate
Description: Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))
Study NCT06778733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)
Description: All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)
Study NCT05772468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality ('VRelax' VR system)
Description: The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
Study NCT04117295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carmat Total Artificial Heart
Description: Heart replacement therapy
Study NCT05890976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide tablets orally once daily for 44 weeks.
Study NCT05890976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide Placebo
Description: Participants will receive placebo matched to semaglutide.
Study NCT04531280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospital care
Description: Patients receive hospital-level care in their home.
Study NCT05885880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue-button screening
Description: Patients will be screened for clinical trial matches using the Blue-button tool
Study NCT06426381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
Study NCT04696042 — intervention group
Intervention type: DRUG
Intervention: Lanreotide autogel
Description: Lanreotide autogel 90-120 mcg, every 4 weeks
Study NCT06354686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS Tolerability
Description: The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the feasibility of the knee as a surrogate location to safely trial TMS parameters.
Study NCT03794726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic Molar Protraction and PAOO
Description: Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
Study NCT03794726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Molar Protraction
Description: Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
Study NCT06079281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1850
Description: ALXN1850 will be administered via subcutaneous (SC) injection.
Study NCT06079281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection.
Study NCT06079281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via SC injection.
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC 5-6 IV
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5-6 IV
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
Study NCT05739981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMNN-001
Description: IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
Study NCT06484075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: Drug approved for improving sleep
Study NCT06484075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a tablet, but only containing inert inactive ingredients.
Study NCT06256432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Endothelin receptor antagonist
Study NCT06256432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin
Study NCT05341726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE Intervention
Description: BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
Study NCT05341726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
Study NCT04555161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aria CV Pulmonary Hypertension System
Description: The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
Study NCT05797168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5335
Description: IV Antibody-drug conjugate
Study NCT05797168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib (AZD5305)
Description: Oral PARP inhibitor
Study NCT05797168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Monoclonal antibody
Study NCT05797168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Alkylating agent
Study NCT06550076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 oral tablet